In the assessment of 12-month price targets, analysts unveil insights for Alnylam Pharmaceuticals, presenting an average target of $420.41, a high estimate of $570.00, and a low estimate of $333.00.

This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to ...

Academic medical centers are becoming more and more expensive than other types of acute-care hospitals. The Boston Business ...

The company formerly known a Sosei Heptares unveiled new weight loss programs. Elsewhere, BridgeBio and Madrigal unveiled ...

Health secretary Robert F. Kennedy Jr. last night announced that the government’s emergency preparedness agency, BARDA, will ...

Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY ) shareholders will have a reason to smile today, with the analysts ...

In July 2025, Pfizer announced a study to establish baseline prospective efficacy data of current FIX prophylaxis replacement ...

Fintel reports that on August 4, 2025, Oppenheimer upgraded their outlook for Alnylam Pharmaceuticals (NasdaqGS:ALNY) from ...

Alnylam Pharmaceuticals (ALNY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Fintel reports that on August 4, 2025, Wolfe Research upgraded their outlook for Alnylam Pharmaceuticals (NasdaqGS:ALNY) from ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $406.0, a high ...

Inclusion isn’t just about eligibility; it’s about participation Trials often demand time, travel and flexibility, resources ...